Navigation Links
Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program

ate the timeline for our anti-viral studies and to request additional funds under the TMTI program. It was therefore an unwelcome surprise to learn that Congress has greatly reduced funding for the TMTI program in 2008, and that as a result, this contract award is no longer feasible."

Peregrine has been informed by its contacts at the DTRA that they worked very hard to find alternative sources of funding for this project, but were unable to do so in the required timeframe. Peregrine has been encouraged to re-apply when new funding initiatives become available.

"While we are very disappointed by this sudden turn of events regarding the potential DTRA contract, it has no impact on our continuing clinical efforts including the development of bavituximab for the treatment of HCV infection and cancer," said Steven W. King, president and CEO of Peregrine. "We appreciate the continued interest expressed from the DTRA in our bavituximab program for viral hemorrhagic fevers and hope to be able to pursue other government funding opportunities when they become available. Based on recent data from our collaborators, we are more enthusiastic than ever about the potential of our anti-PS technology platform for the treatment of viral infections, and we see many potential applications in this area."

* In an October 2, 2007 statement to the Senate on the funding priorities

reflected in the Department of Defense Appropriations Act, 2008

(H.R. 3222), the Office of Management and Budget of the Executive Office

of the President wrote: "The Administration strongly opposes the $100

million reduction to the Transformational Medical Technology Initiative

(TMTI). TMTI represents an essential element of our efforts to develop

countermeasures against new biological threats, such as those that would

be engineered in a laboratory or naturally occurring agents, such as

pandemic viruses, that could have a

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
2. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
3. CHS Receives Prestigious Honor from Department of Defense
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
6. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
7. ICx Awarded Department of Defense Contract for AirSentinel Monitors
8. Taming the anthrax threat
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Taming the anthrax threat
Post Your Comments:
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics that address ... disorders, announced today that it has filed a registration ... Exchange Commission (SEC) relating to the proposed initial public ... of shares to be offered and the price range ... Citigroup and Cowen and Company will act as ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... 27, 2014 announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... Therapeutics Corporation,announced today that it has entered into ... SHPGY, TSX: SHQ), to jointly develop AT-1001,Alba,s lead ... Shire will receive rights to commercialize all forms ... Alba will retain all rights,to commercialize AT-1001 in ...
... Dec. 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... promoted B. Lynne Parshall, J.D. to Chief Operating ... Chief Financial,Officer, and is a Director of the ... reflects the scope,of Lynne,s responsibilities at Isis," commented ...
... PHILADELPHIA, Dec. 14 FMC Corporation (NYSE:,FMC) ... announced the companies,have entered into a worldwide ... a novel capsule technology developed by FMC. ... strengthen,the product life-cycle management of Pronova BioPharma,s ...
Cached Biology Technology:Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 2Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 3Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has ... College of Sports Medicine,s Conference on Integrative Physiology ... Florida. These awards are meant to promote ... from underrepresented groups into the mainstream of the ... of young scientists at the American College of ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Paleontology: Oldest representative of a weird arthropod group 2
... When you think you see a face in the clouds or ... be upside down. It turns out the answer to this ... to. Using tests of visual perception and functional magnetic resonance ... Ontario,s world-renowned Centre for Brain & Mind recently measured activity in ...
... Mention vitamin D-fortified foods and most people think ... vitamin since the 1930s. A new episode in the ... series says that vitamin D-fortified bread could join milk ... is difficult to get naturally in foods. ...
... Minnesota,s College of Biological Sciences, has been awarded a five-year, ... direct a large-scale research effort to study a human antiviral ... The goal of the study will be to produce ... how it interacts with other proteins in human cells and ...
Cached Biology News:U of M scientist gets 5-year, $10 million grant to direct innovative HIV research program 2
... Recognizes an epitope located in ... isotype IV. No reactivity with ... ascites fluid synthetic peptide corresponding ... β-tubulin isotype IV, conjugated to ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
... catalyzes the joining of two strands of ... groups of adjacent nucleotides in either a ... has also been shown to catalyze the ... or RNA strand in a duplex molecule ...
Biology Products: